



KOPRAN LIMITED
UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31st DECEMBER,2014

UNAUDITED FINANCIAL RESULTS FOR	COARTER	ADED STALD	LOCIVIDER	2014		(₹. in lakhs )		
Particulars		Quarter ended	the anded					
	31/12/2014	30/09/2014 31/12/2013		Nine Months ended 31/12/2014 31/12/2013		Year ended 31/03/2014		
<u> </u>	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited			
Net Sales / Income from Operations	6868	7749	7628	21313	21292	Audited		
Other Operating Income	131	192	Į.			2941		
			173	465	570	779		
Total Income from operations	6999	7941	7801	21778	21862	3019		
Expenditure								
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	223	(630)	204	(533)	(423)	(636		
Cost of Materials Consumed	4163	5696	4563	14391	13400	18,750		
Purchase of Stock- in - trade	16	48	219	107	361	578		
Employee Benefits Expenses	751	673	611	2016	1750	2,296		
Depreciation	330	323	315	968	926	1,246		
Other Expenses	1140	1401	1240	3627	3580	4,945		
Total Expenses	6623	7511	7152	20576	19594	27,179		
Profit (Loss) from operations before other income, Interest and exceptional iter	376	430	649	1,202	2,268	3,017		
Other Income	12	45	18	66	22	89		
Foreign Exchange Gain/ (Loss)	88	138	1	417	(158)	44		
Profit (Loss) before Interest and exceptional items	476	613	668	1,685	2,132	3,150		
Finance Cost	324	304	361	921	1,043	1,446		
Profit (Loss) before exceptional items	152	309	307	764	1,089	1,704		
Exceptional items			-		1,000	1,104		
Profit (Loss) before tax	152	309	307	764	1,089	1,704		
Less :Tax expenses				104	1,000	- 1,704		
Net Profit for the period	152	309	307	764	1,089	1,704		
Paid up equity share Capital (Face value Rs 10/-)	4,110	3,905	3,905					
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	4,110	3,803	3,905	4,110	3,905	3,905		
Earning Per Share (EPS) before and after Exceptional Item	_	-				9,752		
a) Basic	0.00	0.70	0.70	4.04	0.70			
b) Diluted	0.38 0.38	0.79	0.79	1.94	2.79	4.36		
Part II	0.30	0.79	0.79	1.94	2.79	4.36		
(A) PARTICULARS OF SHAREHOLDING								
Public shareholding								
Number of shares	23753463	23753463	23753463	23753463	23753463	23753463		
Percentage of shareholding	57.80%	60.83%	60.83%	57.80%	60.83%	60.83%		
Promoters and Promoter Group Shareholding	01.0070	33.3370	00.0070	07.0070	00.0070	00.007		
a) Pledged / Encumbered								
Number of shares	3352500	3352500	3352500	3352500	3352500	3352500		
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.33%	21.92%	21.92%	19.33%	21.92%	21.92%		
Percentage of shares (as a % of the total share capital of the company)	8.16%	8.59%	8.59%	8.16%	8.59%	8.59%		
b) Non - encumbered						2.237		
Number of shares	13993513	11943513	11943513	13993513	11943513	11943513		
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	80.67%	78.08%	78.08%	80.67%	78.08%	78.08%		
Percentage of shares (as a % of the total share capital of the company)	34.05%	30.58%	30.58%	34.05%	30.58%	30.58%		
(B) INVESTOR COMPLAINTS	3 Months ended 31/12/2014							
Pending at the beginning of the quarter			-					
Received during the quarter	1		11					
Disposed off during the quarter			11					
Remaining unresolved at the end of the quarter								





Reporting of Segment wise Revenue, Result and Capital Employed									
Particulars		Quarter ended			Nine Months ended				
	31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014			
1. Segment Revenue	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited			
(a) Pharamaceutical	7,144	8,064	8,019	22,189	22,337	30,880			
(b) Consumer Care Division	60	65	67	186	185	246			
Tot	al 7,204	8,129	8,086	22,375	22,522	31,126			
Less : Inter-Segment Revenue	-	-	-		-	-			
Less: Excise Duty	205	188	285	597	660	930			
Net Sales/ Income from Operation	6,999	7,941	7,801	21,778	21,862	30,196			
2. Segment Results									
(a) Pharamaceutical	526	682	742	1,872	2,308	3,417			
(b) Consumer Care Division	(50)	(69)	(74)	(187)	(176)	(267			
Tot	al 476	613	668	1,685	2,132	3,150			
Less: Finance Cost	324	304	361	921	1,042	1,446			
Total Profit Before Tax	152	309	307	764	1,090	1,704			
3. Capital Employed									
(a) Pharamaceutical	21,490	21,270	21,014	21,490	21,014	21,556			
(b) Consumer Care Division	652	573	258	652	258	397			
(c) Others (Unallocated)	5,407	5,418	5,425	5,407	5,425	5,416			
	al 27,549	27,261	26,697	27,549	26,697	27,369			

#### Notes:

- (1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at it's meeting held on 13th February, 2015 Limited review has been carried out by statutory auditor of the company.
- (2) The company is in process of technically evaluating useful lives of its fixed assets and componentization thereof vis-à-vis the useful lives stated under Schedule II of the Companies Act, 2013. Pending such evaluation, the company has provided depreciation for the quarter by applying the rates that were applicable for the previous financial year. Its impact is unascertainable at this stage and adjustment shall be carried out in subsequent quarter after finalisation of technical evaluation/componentization.
- (3) During the quarter the company has issued and alloted 20,50,000 Equity Shares of Rs.10/- each at premium of Rs.56/- per Equity Share and 21,50,000 Convertible Warrants @ Rs.66/- per warrant on preferential basis to M/s. Oricon Properties Ltd. convertible into equal number of equity shares within 18 months from 26.11.2014.

#### (4) Auditors observation:

a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRLL) as at 31-12-2014 amounting to Rs. 5220.97 Lacs,(as at 31-12-2013 Rs 5238.42 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLL, is long term, for strategic reasons.

(5) Figures for the previous accounting period have been regrouped wherever necessary.

KOPRAN LIMITED

Surendra Somani

**Executive Vice Chairman** 

Place : Mumbai Date: 13-02-2015



# **BATLIBOI & PUROHIT**

## **Chartered Accountants**

## REVIEW REPORT TO THE BOARD OF DIRECTORS OF

### **KOPRAN LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **Kopran Limited** ("the **Company"**) for the quarter ended 31 December, 2014 ('the statement') except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

- 2. Attention is invited to note 3 in the statement regarding Investment and Advances aggregating Rs. 500.61 lakhs and Rs. 4,720.36 lakhs respectively given to a subsidiary company, Kopran Research Laboratories Limited whose accumulated losses have exceeded the net-worth, no provision for Investments and Doubtful Advances has been made by the management of the Company. Consequently, the effect, if any, on the carrying values of investments and advances given are currently unascertainable.
- 3. The Company is in the process of evaluating the useful lives of all its fixed assets pursuant to schedule II of the Companies Act, 2013 and pending such evaluation, the impact of depreciation on the financial results of the quarter is not ascertained.
- 4. Based on our review conducted as above and on consideration of other financial information except for the effect of the matter described in Para 2 and 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standard, notified pursuant to the Company's (Accounting Standards) Rules, 2006 (which are deemed to be applicable as per section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BATLIBOI & PUROHIT

Chartered Accountants
Firm Reg No. 101048W

KAUSHAL MEHTA

A. A. Mel

Partner

Membership No. 111749

Place: Mumbai

Dated: 13th February, 2015